The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin

Cancer Research

Volumn 56, Issue 9, 1996, Pages 2105-2111

  Szallasi, Zoltan ^a   Du, Linh ^a   Levine, Rachel ^a   Lewin, Nancy E ^a   Nguyen, Phi Nga ^a   Williams, Michael D ^b   Pettit, George R ^b   Blumberg, Peter M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN; BRYOSTATIN 1; PROTEIN KINASE C;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; DISSOCIATION; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME MECHANISM; GENE TRANSLOCATION; GROWTH INHIBITION; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; LACTONES; MACROLIDES; MELANOMA, EXPERIMENTAL; MICE; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0029892167     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Barnhill, R. L., Mihm, M. C , Jr., Fitzpatrick, T B., and Sober, A. J. Neoplasms, malignant melanoma. In: T. B. Fitzpatrick, A Z Eisen, K. Wollf, I M. Freedberg, and K. F. Austen (eds.), Dermatology in General Medicine, pp. 1078-1115 New York. McGraw-Hill, Inc , 1993.
2. Hornung, R. L , Pearson, J W., Beckwith, M., and Longo, D L Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
3. Schuchter, L. M., Esa, A. H , May, S., Laulis, M. K., Pettit, G. R., and Hess, A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res., 51: 682-687, 1991.
4. Prendivlle, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stern, P., McDermott, R , Potter, M., and Pettit, G. R. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
5. Philip, P. A., Rea, D , Thavasu, P., Carmichel, J., Stuart, N S. A., Rockett, H., Talbot, D. C., Ganesan, T. Pettit, G. R , Balkwill, F., and Harris, A. L. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J. Natl. Cancer Inst., 85, 1812-1818, 1993.
6. 3H]bryostatin 4 to protein kinase C. Biochem Pharmacol., 43: 2007-2014, 1992.
7. Kraft, A S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. USA, 83 1334-1338, 1986.
8. 3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol., 46: 374-379, 1994
9. Blumberg, P. M., and Pettit, G. R. The bryostatins, a family of protein kinase C activators with therapeutic potential In: P. Krogsgaard-Larsen, C. Brogger Christensen, and H. Kofod (eds ), New Leads and Targets in Drug Research, Alfred Benzon Symposium 33, pp. 273-285. Copenhagen, Denmark: Munksgaard, 1992.
10. Szallasi, Z , Denning, M. F., Smith C. B., Dlugosz, A. A., Yuspa, S. H., Pettit, G. R., and Blumberg, P. M. Bryostatin 1 protects protein kinase C-δ from down-regulation in mouse keratinocytes in parallel with us inhibition of phorbol ester induced differentiation. Mol. Pharmacol , 46: 840-850, 1994.
11. Szallasi, Z., Smith, C B., Pettit, G R., and Blumberg, P. M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol Chem., 269: 2118-2124, 1994.
12. Dell'Aquilla, M. L., Nguyen, H. T., Herald, C. H., Pettit, G. R , and Blumberg, P. M. Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells Cancer Res., 47: 6006-6009, 1987.
13. Dell'Aquilla, M. L., Herald, C. H., Kamano, Y , Pettit, G. R., and Blumberg, P M. Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H10T/2 cells. Cancer Res., 48: 3702-3708, 1988.
14. Kazanietz, M G., Areces, L. B , Bahador, A., Mishak, H , Goodnight, J., Mushinski, J. F , and Blumberg, P M Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. Mol. Pharmacol., 44: 298-307, 1993.
15. Hergenhahn, M., Furstenberger, G., Opferfcuch, H. J., Adolf, W., Mack, H., and Hecker, E. Biological assays for irritant tumor-initiating and -promoting activities. I. Kinetics of the irritant response in relation to the initiation-promoting activity of polyfunctional diterpenes representing tigliane and some daphnane types. J. Cancer Res. Clin. Oncol., 104: 31-39, 1982.
16. Furstenberger, G., and Hecker, E Zum Wirkungsmechanismus Cocarcinogener Pflanzenmhaltsstoffe. Planta Med., 22: 241-266, 1972.
17. Zayed, S., Sorg, B., and Hecker, E. Structure activity relations of polyfunctional diterpenes of the tiguane type, VI. Planta Med., 34: 65-69, 1984
18. Zhang, G., Kazanietz, M G , Blumberg, P. M., and Hurley, J H. Structural basis for membrane and tumor-promoter binding by protein kinase C. Cell, 81: 917-924, 1995.
19. Rando, R. R., and Kishi, Y. Structural basis of protein kinase C activation by diacylglycerol and tumor promoters. Biochemistry, 11: 2211-2218, 1992.
20. Wender, P. A., Cribbs, C. M., Koehler, K. F., Sharkey, N. E., Herald, C. L., Kamano, Y., Pettit, G. R., and Blumberg, P. M. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C Proc. Natl. Acad. Sci USA, 85: 7197-7201, 1988.
21. 3H]epibryostatin 4 to protein kinase C. Cancer Commun., 3: 67-70, 1991.
22. Pettit, G. R., Herald, C. L., Doubek, D. L., Arnold, E , and Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982
23. Pettit, G. R , Sengupta, D., Blumberg, P. M., Lewin, N E., Schmidt, J. M , and Kraft, A S. Structural modifications of bryostatin 2. Anti-Cancer Drug Des., 7: 101-113. 1992.
24. Fidler, I. J. Selection of successive tumor lines for metastasis. Nature (Lond ), 242: 148-149, 1973.
25. Nakadate, T., Jeng, A. Y., and Blumberg, P. M. Comparison of protein kinase C functional assays to clarify mechanisms of inhibitor action. Biochem. Pharmacol., 37: 1541-1545, 1988.
26. Toullec, D., Pianetti, P , Coste, H., Bellevergue, P., Grand-Perret, T , Ajakane, M., Baudet, V , Boissini, P., Boursier, E., Loriolle, F., Duhamel, L , Charon, D , and Kirilovsky, J The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C J. Biol Chem , 266: 15771-15781, 1991.